Acquisition of Symetis

Boston Scientific Corporation

Our attorneys advised Boston Scientific in the company’s $435 million acquisition of Symetis, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation devices. As indicated by Boston Scientific’s press release, “[T]his compelling combination of technologies will allow us to provide interventional cardiologists and cardiac surgeons with multiple TAVI offerings for varying patient pathologies and anatomy.”

Email Disclaimer